These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27461704)

  • 1. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
    Bugalho MJ
    J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
    Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    Higuchi Y; Motoki T; Ishida H; Kanamitsu K; Washio K; Oyama T; Noda T; Tsurumaru Y; Okada A; Tsukahara H; Shimada A
    BMC Cancer; 2017 Nov; 17(1):775. PubMed ID: 29162036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Pitoia F
    Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.